Boehringer Ingelheim broadens oncology portfolio with license for Synaffix's ADC technology
Boehringer Ingelheim has licensed Synaffix's ADC technology to expand its oncology portfolio. The partnership aims to develop advanced antibody-drug conjugates (ADCs) for cancer treatment, combining antibodies' targeting ability with potent cancer-killing drugs for precise delivery to cancer cells.
The agreement involves Synaffix providing access to its proprietary ADC technologies for multiple targets, with the first target already nominated. The deal includes an upfront payment and potential milestone payments up to $1.3 billion, plus royalties on net sales of resulting products.
Synaffix's technology utilizes enzymatic modification of native glycan anchor points on antibodies, enabling the development of enhanced ADCs or bispecifics. This collaboration will allow Boehringer's subsidiary, NBE Therapeutics, to address novel tumor targets and develop first-in-class cancer treatments for high unmet medical needs in oncology.
Boehringer Ingelheim ha concesso in licenza la tecnologia ADC di Synaffix per espandere il suo portafoglio oncologico. La partnership mira a sviluppare coniugati anticorpo-farmaco (ADCs) avanzati per il trattamento del cancro, combinando la capacità di targeting degli anticorpi con potenti farmaci anti-cancro per una consegna precisa alle cellule tumorali.
L'accordo prevede che Synaffix fornisca accesso alle sue tecnologie proprietarie ADC per più bersagli, con il primo bersaglio già nominato. L'affare include un pagamento iniziale e potenziali pagamenti per traguardi fino a 1,3 miliardi di dollari, più royalties sulle vendite nette dei prodotti risultanti.
La tecnologia di Synaffix utilizza la modifica enzimatica dei punti di ancoraggio glicano nativi sugli anticorpi, consentendo lo sviluppo di ADC migliorati o bispecifici. Questa collaborazione permetterà alla sussidiaria di Boehringer, NBE Therapeutics, di affrontare nuovi bersagli tumorali e sviluppare trattamenti oncologici pionieristici per elevate necessità mediche insoddisfatte.
Boehringer Ingelheim ha licenciado la tecnología ADC de Synaffix para expandir su cartera oncológica. La asociación tiene como objetivo desarrollar conjugados anticuerpo-fármaco (ADCs) avanzados para el tratamiento del cáncer, combinando la capacidad de selección de los anticuerpos con potentes fármacos antitumorales para una entrega precisa a las células cancerosas.
El acuerdo implica que Synaffix proporcione acceso a sus tecnologías ADC patentadas para múltiples objetivos, con el primer objetivo ya nominado. El acuerdo incluye un pago inicial y pagos por hitos potenciales de hasta 1,3 mil millones de dólares, además de regalías sobre las ventas netas de los productos resultantes.
La tecnología de Synaffix utiliza la modificación enzimática de los puntos de anclaje de glicanos nativos en los anticuerpos, lo que permite el desarrollo de ADC mejorados o bispecíficos. Esta colaboración permitirá a la subsidiaria de Boehringer, NBE Therapeutics, abordar nuevos objetivos tumorales y desarrollar tratamientos oncológicos de primera clase para altas necesidades médicas no satisfechas.
베링거 인겔하임은 시나픽스의 ADC 기술의 라이센스를 취득하여 종양학 포트폴리오를 확장하고자 합니다. 이 파트너십은 항체의 표적 능력과 강력한 항암제를 결합하여 암세포에 정확하게 약물을 전달하는 고급 항체-약물 접합체 (ADCs)를 개발하는 것을 목표로 하고 있습니다.
이 협정은 시나픽스가 여러 표적에 대한 독점 ADC 기술에 대한 접근을 제공하며, 첫 번째 표적이 이미 선정되었습니다. 이번 계약에는 선불금과 함께 13억 달러까지의 잠재적 이정표 지급금이 포함되며, 결과 제품의 순매출에 대한 로열티도 포함됩니다.
시나픽스의 기술은 항체의 본래의 글리칸 앵커 포인트를 효소적으로 변형하여 향상된 ADC 또는 이중특이성을 개발할 수 있도록 합니다. 이 협력은 베링거의 자회사인 NBE 테라퓨틱스가 새로운 종양 표적을 다루고, 높은 의료적 필요가 있는 종양학에 대한 최초의 항암 치료제를 개발할 수 있게 해줄 것입니다.
Boehringer Ingelheim a licencié la technologie ADC de Synaffix pour élargir son portefeuille en oncologie. Le partenariat vise à développer des conjugués anticorps-médicament (ADCs) avancés pour le traitement du cancer, en combinant la capacité de ciblage des anticorps avec des médicaments anticancéreux puissants pour une livraison précise aux cellules cancéreuses.
Le contrat implique que Synaffix fournisse un accès à ses technologies ADC propriétaires pour plusieurs cibles, la première cible ayant déjà été nommée. L'accord comprend un paiement initial et des paiements d'étapes potentiels pouvant atteindre 1,3 milliard de dollars, ainsi que des redevances sur les ventes nettes des produits résultants.
La technologie de Synaffix utilise la modification enzymatique des points d'ancrage glycanes natifs sur les anticorps, permettant le développement d'ADCs améliorés ou bispécifiques. Cette collaboration permettra à la filiale de Boehringer, NBE Therapeutics, de cibler de nouvelles cibles tumorales et de développer des traitements anticancéreux de première classe pour des besoins médicaux non satisfaits dans le domaine de l'oncologie.
Boehringer Ingelheim hat die ADC-Technologie von Synaffix lizenziert, um sein Onkologie-Portfolio zu erweitern. Die Partnerschaft zielt darauf ab, fortschrittliche Antikörper-Wirkstoff-Konjugate (ADCs) zur Krebsbehandlung zu entwickeln, indem die Zielgenauigkeit von Antikörpern mit potenten krebsbekämpfenden Medikamenten kombiniert wird, um eine präzise Abgabe an die Krebszellen zu ermöglichen.
Die Vereinbarung sieht vor, dass Synaffix Zugang zu seinen proprietären ADC-Technologien für mehrere Ziele gewährt, wobei das erste Ziel bereits benannt wurde. Der Vertrag umfasst eine Vorauszahlung und potenzielle Meilensteinzahlungen von bis zu 1,3 Milliarden US-Dollar, sowie Tantiemen auf den Nettoverkauf der resultierenden Produkte.
Die Technologie von Synaffix nutzt die enzymatische Modifikation nativer Glykanchorpunkte an Antikörpern, wodurch die Entwicklung verbesserter ADCs oder bispezifischer Antikörper ermöglicht wird. Diese Zusammenarbeit wird es der Tochtergesellschaft von Boehringer, NBE Therapeutics, ermöglichen, neuartige Tumorziele anzugehen und erstmalige Krebstherapien für hohe medizinische Bedürfnisse in der Onkologie zu entwickeln.
- Potential milestone payments of up to $1.3 billion plus royalties
- Access to clinically validated ADC platform technology
- Expansion into novel tumor target space
- None.
ADCs are a cutting-edge class of cancer treatments that combine the targeting ability of antibodies with the potent cancer-killing power of drugs. This allows for the precise delivery of therapeutic agents directly to cancer cells, minimizing damage to healthy tissue and enhancing treatment efficacy.
Peter van de Sande, Head of Synaffix, said: "Boehringer Ingelheim is a leader in oncology treatment development, and the selection of our ADC technologies to further bolster their pipeline portfolio is a strong recognition of the potential of these technologies to maximize the therapeutic index of ADCs. This licensing agreement represents the culmination of a successful preclinical evaluation of our technology."
Lamine Mbow, Global Head of Discovery Research, Boehringer Ingelheim, said: "We are building a broad pipeline of ADCs addressing the novel tumor target space to develop next-generation cancer treatments. By combining our deep expertise in cancer treatment development with Synaffix's clinical-stage platform technology, we aim to accelerate the delivery of first-in-class cancer treatments to improve cancer patient outcomes."
Synaffix has developed a clinically validated ADC platform technology that utilizes an enzymatic modification of native glycan anchor points on antibodies, enabling the development of best-in-class ADCs or bispecifics. With the access to Synaffix's technology, NBE Therapeutics broadens its ADC portfolio. This will enable Boehringer Ingelheim to address novel tumor targets from its comprehensive portfolio to develop first-in-class cancer treatments that address high unmet medical needs in oncology.
Under the terms of the agreement, Synaffix will provide access to its proprietary ADC technologies for an agreed but undisclosed number of targets. The first target was nominated upon signature, and additional targets will subsequently be nominated within a predefined timeframe. In addition to the upfront payment, Synaffix is eligible to receive potential additional milestone payments of up to
Notes to Editors:
About Boehringer Ingelheim
Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in Research and Development, the company focuses on developing innovative therapies in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. More than 53,500 employees serve over 130 markets to build a healthier, more sustainable, and equitable tomorrow. Learn more at https://www.boehringer-ingelheim.com.
About Synaffix
Synaffix B.V. is a biotechnology company that enables ADC product candidates using its clinical-stage, site-specific ADC technology platform based on GlycoConnect™, HydraSpace® and toxSYN® technologies, that together enable any company with an antibody to develop proprietary best-in-class ADC products under a single license from Synaffix.
The Synaffix platform enables a rapid timeline to clinic due to the established supply chain of technology components. Synaffix holds granted patents to its technology. The business model of Synaffix is target-specific technology out-licensing, as exemplified through its partnered pipeline.
Synaffix was fully acquired by Lonza in June 2023.
For more information about Synaffix's ADC platform technology, please visit:
https://www.synaffix.com/platform/technology/
About Lonza
Lonza is one of the world's largest healthcare manufacturing organizations. Working across five continents, our global community of around 18,000 colleagues helps pharmaceutical, biotech and nutrition companies to bring their treatments to market. United by our vision to bring any therapy to life, we support our customers with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from lifesaving and life-enhancing treatments.
Our business is structured to meet our customers' complex needs. Our company generated sales of
Follow @Lonza on LinkedIn.
Follow @LonzaGroup on X
View original content:https://www.prnewswire.com/news-releases/boehringer-ingelheim-broadens-oncology-portfolio-with-license-for-synaffixs-adc-technology-302346940.html
SOURCE Synaffix B.V.
FAQ
What is the value of the milestone payments in the Boehringer-Synaffix ADC technology deal?
How will Synaffix's ADC technology benefit Boehringer Ingelheim's cancer research?
What are the key terms of the Boehringer-Synaffix licensing agreement?
How will this partnership affect Boehringer's oncology portfolio?
